STAT5B and neoplasm: One preclinical study showed that lestaurtinib treatment of anaplastic thyroid cancer cell lines inhibited STAT5 phosphorylation/activation, cell proliferation, cell survival, and cell migration, in addition to tumor growth in in vivo models[166].